Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by gregoooon May 03, 2013 8:46am

94 Views

Post# 21334128

RE: RE: so what's so hard to understand

its quite clear "They don't have any money" to do what they want. This is from the MD&A. People should read this document before making statements- they have plans for Canaguay #2, they are working on a development plan for Flami including processing and water disposal - go to Sedar and read the reports.imo

Requirement of additional equity financing

Although the Company is producing and selling crude oil in Colombia, the revenues are not sufficient to cover the operating and administrative expenses and the planned capital expenditures. Management is considering all possibilities for raising additional capital including capital market transactions, seeking other partners or disposition of some of its assets.

Bullboard Posts

Consumer advocacy law firm investigates Microsoft over X-Box data concerns